Drug Profile
Ruxolitinib - Incyte Corporation/Novartis
Alternative Names: INC-424; INCB 018424 phosphate; INCB-018424; INCB-18424; Jakafi; Jakavi; Opzelura; RUX; ruxolitinib phosphateLatest Information Update: 19 Mar 2024
Price :
$50
*
At a glance
- Originator Incyte Corporation
- Developer Baylor Breast Care Center; CMS Medical; Dana-Farber Cancer Institute; H. Lee Moffitt Cancer Center and Research Institute; Incyte Corporation; Lymphoma Academic Research Organisation; National Cancer Institute (USA); Novartis; RWTH Aachen University; University Health Network of Toronto; University of Cologne; University of Texas M. D. Anderson Cancer Center; Washington University School of Medicine
- Class 2 ring heterocyclic compounds; Anti-inflammatories; Antianaemics; Antibronchitics; Antihaemorrhagics; Antineoplastics; Antipsoriatics; Antirheumatics; Antivirals; Cyclopentanes; Nitriles; Pyrazoles; Pyrimidines; Pyrroles; Skin disorder therapies; Small molecules
- Mechanism of Action Janus kinase 1 inhibitors; Janus kinase-2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Atopic dermatitis; Graft-versus-host disease; Myelofibrosis; Polycythaemia vera; Vitiligo
- Phase III Cytokine release syndrome; Essential thrombocythaemia; Prurigo nodularis; SARS-CoV-2 acute respiratory disease
- Phase II/III COVID-19 pneumonia
- Phase II Acute myeloid leukaemia; Alopecia areata; Breast cancer; Breast disorders; Bronchiolitis obliterans; Cachexia; Chronic lymphocytic leukaemia; Chronic myeloid leukaemia; Chronic myelomonocytic leukaemia; Discoid lupus erythematosus; Haematological malignancies; Head and neck cancer; Hidradenitis suppurativa; HIV infections; Hodgkin's disease; Lichen planus; Myelodysplastic syndromes; Precursor cell lymphoblastic leukaemia-lymphoma; Thalassaemia; Vulvar lichen sclerosus
- Phase I/II Anaemia; HER2 positive breast cancer; Multiple myeloma
- Phase I Adenocarcinoma
- No development reported Psoriasis
- Discontinued Colorectal cancer; HER2 negative breast cancer; Non-small cell lung cancer; Pancreatic cancer; Prostate cancer; Rheumatoid arthritis
Most Recent Events
- 15 Mar 2024 Incyte Corporation initiates a phase I trial (In volunteers) in the US (PO) (NCT06310304)
- 10 Mar 2024 Efficacy and adverse event data form a phase II trial in Hidradenitis suppurativa presented at the American Academy of Dermatology (AAD-2023)
- 26 Feb 2024 Incyte Corporation completes a phase II trial in Lichen planus in USA and Canada (Topical) (NCT05593432)